Advances in small molecule maintenance therapies for high-grade serous ovarian cancer. (2nd January 2023)

• Record Type: Journal Article
• Authors: Fischetti, Margherita; Di Donato, Violante; Palaia, Innocenza; Perniola, Giorgia; Tomao, Federica; Perrone, Chiara; Giancotti, Antonella; Di Mascio, Daniele; Monti, Marco; Muzii, Ludovico; Benedetti Panici, Pierluigi; Bogani, Giorgio
• Is Part Of: Expert opinion on pharmacotherapy. Volume 24:Number 1(2023)
• Page Start: 65
• Page End: 72
• Publication Date: 2023-01-02
• Subjects: Small molecule -- ovarian cancer -- TKI -- BRCA -- PARP; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2022.2154144
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: Ovarian cancer is one of the most lethal gynecological tumors with a lack of effective treatment modalities especially in advanced/recurrent disease. Nevertheless, recently, new small molecules have emerged as an effective approach for the management of ovarian cancer patients, especially in the maintenance setting. Areas covered: This review summarizes the role of small molecules used in the management of high-grade serous ovarian cancer. The authors performed a critical review of current evidence and ongoing studies. Of note, tyrosine kinase inhibitors (TKIs) and poly(ADP-ribose) polymerase (PARP) inhibitors are the most intriguing medications in this setting. Expert opinion: Protein-targeted therapies against tumor tissues have progressed significantly in the last years due to an enhanced knowledge of the biological and molecular processes of carcinogenesis. Treatment with small molecules allows the targeting of specific proteins involved in cancer biology. TKIs seem promising but further data are necessary to assess the pros and cons of adopting this treatment modality. PARP inhibitors represent the new standard of care for ovarian cancer patients harboring either a BRCA mutation or with homologous recombination deficiency (HRD). Interestingly, the accumulation of data has highlighted that PARP inhibitors provide benefits even in patients with HR proficient tumors.